GlassScriptPhysician profile
Mallory B Merrill
NPI 1760948178
$3,839.23
in general payments reported to CMS, 2019-2025
24 companies · $63.91 in 2025
The $63.91 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.49 · 2022: $848 · 2023: $1,031 · 2024: $1,880 · 2025: $63.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,975.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $786.55 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $535.12 | 2022-2024 | Xifaxan, Trulance |
| Celgene Corporation | $458.19 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $409.26 | 2022-2024 | Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $354.39 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $207.46 | 2023-2024 | Linzess |
| Janssen Biotech, INC. | $171.97 | 2023-2024 | Stelara, Tremfya, Simponi |
| Ardelyx, INC. | $162.87 | 2023-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $111.65 | 2022-2024 | Dupixent |
| Genzyme Corporation | $111.49 | 2024 | |
| Glaxosmithkline, LLC. | $95.23 | 2021-2023 | Trelegy Ellipta, Arexvy |
| Intercept Pharmaceuticals, INC. | $76.36 | 2022-2024 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $55.83 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $48.06 | 2022-2023 | Rebyota |
| Qol Medical, LLC | $39.31 | 2024 | Sucraid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $34.42 | 2024 | Resmetirom |
| Orphalan INC | $33.12 | 2024 | Cuvrior |
| Lilly USA, LLC | $28.02 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.38 | 2024 | Cyltezo |
| Amgen INC. | $22.00 | 2025 | Uplizna |
| Gilead Sciences, INC. | $21.27 | 2024 | |
| Digestive Care, INC. | $20.25 | 2024 | Pertzye |
| Braintree Laboratories, INC. | $16.55 | 2022 | |
| Evoke Pharma, INC. | $14.48 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Merrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.